Home › Companies › Trevi Therapeutics, Inc. › 2025-2026

Trevi Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Trevi Therapeutics, Inc.’s Form 8-K, filed June 4, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

5Reported items
193Asset managers
1,085Fund votes
June 3, 2026Meeting date

Results at a glance

Meeting of June 3, 2026: 5 items on Trevi Therapeutics, Inc.’s Form 8-K, filed June 4, 2026: 4 approved · 1 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2024-2025 2025-2026

Explore Trevi Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Trevi Therapeutics, Inc.

These tallies are Trevi Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Trevi Therapeutics, Inc. — official shareholder meeting results, meeting held June 3, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Proposal 1	81,567,765	--	--	18,635,726	14,140,404	81%	Not verified	—
2. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026	114,001,970	223,323	118,602	--	--	99.8%	Approved	—
3. Compensation of the Company's named executive officers	98,119,461	1,982,126	101,904	--	14,140,404	98%	Approved	—
4. A&R 2019 Plan	98,140,470	1,961,030	101,991	--	14,140,404	98%	Approved	—
5. Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares	110,453,620	3,872,599	17,676	--	--	97%	Approved	—

Source: Trevi Therapeutics, Inc., Form 8-K, filed with the SEC on June 4, 2026 — read the filing on EDGAR.

How asset managers voted at the Trevi Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 193 asset managers that disclosed a Trevi Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Trevi Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Election of one Class I director to our Board of Directors, to serve until the 2029 Annual Meeting…: Michael Heffernan

No official matchDIRECTOR ELECTIONS

Combines 5 wordings of this item as funds reported it.

84% of fund votes cast · no official result

FORWITHHOLD

Details: description as filed, votes by 54 asset managers

Description as filed by funds: Election of one Class I director to our Board of Directors, to serve until the 2029 Annual Meeting of Stockholders: Michael Heffernan

The 54 asset managers below reported 22,289,085 for, 4,222,117 withheld, 36 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 22,289,085ABSTAIN: 36WITHHOLD: 4,222,117

Largest asset managers voting on “Election of one Class I director to our Board of Directors, to serve until the 2029 Annual Meeting of Stockhol” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	9,723,168	0	0	For
Vanguard	5,885,667	36	0	For
MUTUAL FUND SERIES TRUST	2,622,306	0	23,970	For
BlackRock	2,093,710	0	0	For
AllianceBernstein	0	0	1,503,499	Withhold
Charles Schwab	840,997	0	0	For
Principal	0	0	804,021	Withhold
RBB FUND, INC.	0	0	756,714	Withhold
Hartford	0	0	233,747	Withhold
Equitable	152,842	0	80,440	Mixed
Allspring	0	0	222,155	Withhold
OPTIMUM FUND TRUST	170,067	0	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	0	For
State Street	185	0	125,042	Withhold
Lincoln Financial	0	0	108,812	Withhold
Brighthouse	0	0	108,251	Withhold
Empower	89,530	0	0	For
TIAA	70,732	0	0	For
Invesco	69,371	0	0	For
Simplify Exchange Traded Funds	65,412	0	0	For
AMG Funds I	53,566	0	0	For
AIG/SunAmerica	0	0	49,804	Withhold
Goldman Sachs	28,890	0	20,610	Mixed
MASTER INVESTMENT PORTFOLIO	48,119	0	0	For
Global X	44,565	0	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

2. 5. Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 110,453,620AGAINST: 3,872,599

Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 200,000,000 SHARES TO 400,000,000 SHARES.

Trevi Therapeutics, Inc.’s own tally for this item (“5. Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares”): 110,453,620 for, 3,872,599 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares was approved.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 25,214,882 for, 1,296,356 against.

FOR

FOR: 25,214,882AGAINST: 1,296,356

Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF A” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	9,723,168	0	For
Vanguard	5,877,013	8,690	For
MUTUAL FUND SERIES TRUST	2,646,276	0	For
BlackRock	2,093,710	0	For
AllianceBernstein	1,503,499	0	For
Charles Schwab	840,997	0	For
Principal	352,376	451,645	Mixed
RBB FUND, INC.	0	756,714	Against
Hartford	233,747	0	For
Equitable	233,282	0	For
Allspring	222,155	0	For
OPTIMUM FUND TRUST	170,067	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	For
State Street	125,141	86	For
Lincoln Financial	108,812	0	For
Brighthouse	29,636	78,615	Mixed
Empower	89,530	0	For
TIAA	70,732	0	For
Invesco	69,371	0	For
Simplify Exchange Traded Funds	65,412	0	For
AMG Funds I	53,566	0	For
AIG/SunAmerica	49,804	0	For
Goldman Sachs	49,500	0	For
MASTER INVESTMENT PORTFOLIO	48,119	0	For
Global X	44,565	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

3. 4. A&R 2019 Plan

Official result Fund totals may overlapCOMPENSATIONReported outcome: Approved

98% Approved · of votes cast

FOR 98%

FOR: 98,140,470AGAINST: 1,961,030

Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: APPROVAL OF THE TREVI THERAPEUTICS, INC. AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN.

Trevi Therapeutics, Inc.’s own tally for this item (“4. A&R 2019 Plan”): 98,140,470 for, 1,961,030 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The A&R 2019 Plan was approved.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 52 asset managers voting on “APPROVAL OF THE TREVI THERAPEUTICS, INC. AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN.” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	9,723,168	0	0	For
Vanguard	5,885,699	4	0	For
MUTUAL FUND SERIES TRUST	2,646,276	0	0	For
BlackRock	2,093,710	0	0	For
AllianceBernstein	1,503,499	0	0	For
Charles Schwab	840,997	0	0	For
Principal	804,021	0	0	For
RBB FUND, INC.	756,714	0	0	For
Hartford	233,747	0	0	For
Equitable	233,282	0	0	For
Allspring	222,155	0	0	For
OPTIMUM FUND TRUST	170,067	0	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	0	For
State Street	125,206	21	0	For
Lincoln Financial	108,812	0	0	For
Brighthouse	29,636	0	78,615	Mixed
Empower	89,530	0	0	For
TIAA	70,732	0	0	For
Invesco	69,371	0	0	For
Simplify Exchange Traded Funds	65,412	0	0	For
AMG Funds I	53,566	0	0	For
AIG/SunAmerica	49,804	0	0	For
Goldman Sachs	49,500	0	0	For
MASTER INVESTMENT PORTFOLIO	48,119	0	0	For
Global X	44,565	0	0	For

Fund voting reports, all 52 managers: 26,418,337 for, 25 against, 78,615 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 3 asset managers voting on “APPROVAL OF THE TREVI THERAPEUTICS, INC. AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN.” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Vote
NEA Management Company, LLC	13,225,026	For
Vident Advisory, LLC	2,298	For
Keel Point, LLC	1,082	For

Institutional-manager reports, all 3 managers: 13,228,406 for.

4. 3. Compensation of the Company's named executive officers

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%

FOR: 98,119,461AGAINST: 1,982,126

Details: description as filed, official tally, votes by 193 asset managers

Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

Trevi Therapeutics, Inc.’s own tally for this item (“3. Compensation of the Company's named executive officers”): 98,119,461 for, 1,982,126 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers was approved, on an advisory basis.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 53 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	9,723,168	0	0	For
Vanguard	5,885,699	4	0	For
MUTUAL FUND SERIES TRUST	2,646,276	0	0	For
BlackRock	2,093,710	0	0	For
AllianceBernstein	1,503,499	0	0	For
Charles Schwab	840,997	0	0	For
Principal	804,021	0	0	For
RBB FUND, INC.	756,714	0	0	For
Hartford	233,747	0	0	For
Equitable	233,282	0	0	For
Allspring	222,155	0	0	For
OPTIMUM FUND TRUST	170,067	0	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	0	For
State Street	125,201	26	0	For
Lincoln Financial	108,812	0	0	For
Brighthouse	29,636	0	78,615	Mixed
Empower	89,530	0	0	For
TIAA	70,732	0	0	For
Invesco	0	69,371	0	Against
Simplify Exchange Traded Funds	65,412	0	0	For
AMG Funds I	53,566	0	0	For
AIG/SunAmerica	49,804	0	0	For
Goldman Sachs	49,500	0	0	For
MASTER INVESTMENT PORTFOLIO	48,119	0	0	For
Global X	44,565	0	0	For

Fund voting reports, all 53 managers: 26,362,141 for, 69,401 against, 78,615 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 157 asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
NEA Management Company, LLC	13,225,026	0	For
Frazier Life Sciences Management, L.P.	9,939,547	0	For
Fidelity	8,053,640	0	For
Vivo Capital, LLC	5,094,668	0	For
BlackRock	3,278,721	25,528	For
VIKING GLOBAL INVESTORS LP	3,198,644	0	For
MPM BioImpact LLC	2,930,957	0	For
Wellington	2,772,637	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,675,847	0	For
AllianceBernstein	2,635,253	0	For
Artia Global Partners LP	2,013,602	0	For
Siren, L.L.C.	1,786,867	0	For
State Street	1,581,529	17,483	For
PICTET ASSET MANAGEMENT SA	1,530,435	0	For
Octagon Capital Advisors LP	1,485,000	0	For
ORBIMED ADVISORS LLC	1,403,717	0	For
Rubric Capital Management LP	1,288,918	0	For
NAN FUNG TRINITY (HK) Ltd	1,142,950	0	For
Vestal Point Capital, LP	1,113,973	0	For
Logos Global Management LP	966,371	0	For
EMERALD ADVISERS, LLC	873,193	0	For
Charles Schwab	863,324	0	For
Vanguard	851,928	0	For
Candriam S.C.A.	0	773,620	Against
Putnam	728,406	0	For

Institutional-manager reports, all 157 managers: 78,328,974 for, 1,395,482 against, 69 abstained. Showing the 25 largest; see all in the interactive database.

5. 2. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%

FOR: 114,001,970AGAINST: 223,323

Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Trevi Therapeutics, Inc.’s own tally for this item (“2. Appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026”): 114,001,970 for, 223,323 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 26,432,603 for, 21 against, 78,615 abstained.

FOR

FOR: 26,432,603AGAINST: 21ABSTAIN: 78,615

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	9,723,168	0	0	For
Vanguard	5,885,703	0	0	For
MUTUAL FUND SERIES TRUST	2,646,276	0	0	For
BlackRock	2,093,710	0	0	For
AllianceBernstein	1,503,499	0	0	For
Charles Schwab	840,997	0	0	For
Principal	804,021	0	0	For
RBB FUND, INC.	756,714	0	0	For
Hartford	233,747	0	0	For
Equitable	233,282	0	0	For
Allspring	222,155	0	0	For
OPTIMUM FUND TRUST	170,067	0	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	0	For
State Street	125,206	21	0	For
Lincoln Financial	108,812	0	0	For
Brighthouse	29,636	0	78,615	Mixed
Empower	89,530	0	0	For
TIAA	70,732	0	0	For
Invesco	69,371	0	0	For
Simplify Exchange Traded Funds	65,412	0	0	For
AMG Funds I	53,566	0	0	For
AIG/SunAmerica	49,804	0	0	For
Goldman Sachs	49,500	0	0	For
MASTER INVESTMENT PORTFOLIO	48,119	0	0	For
Global X	44,565	0	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

Largest Trevi Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 128,411,048 shares outstanding at the time of that meeting.

Fund voting reports: top Trevi Therapeutics, Inc. shareholders by shares voted on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.”, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	7.57%
2	Vanguard	4.58%
3	MUTUAL FUND SERIES TRUST	2.06%
4	BlackRock	1.63%
5	AllianceBernstein	1.17%
6	Charles Schwab	0.65%
7	Principal	0.63%
8	RBB FUND, INC.	0.59%
9	Hartford	0.18%
10	Equitable	0.18%

Institutional-manager reports: top Trevi Therapeutics, Inc. shareholders by shares voted on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.”, 2025-2026
#	Asset manager	% of shares outstanding
1	NEA Management Company, LLC	10.30%
2	Frazier Life Sciences Management, L.P.	7.74%
3	Fidelity	6.27%
4	Vivo Capital, LLC	3.97%
5	BlackRock	2.57%
6	VIKING GLOBAL INVESTORS LP	2.49%
7	MPM BioImpact LLC	2.28%
8	Wellington	2.16%
9	GEODE CAPITAL MANAGEMENT, LLC	2.08%
10	AllianceBernstein	2.05%

Reported Trevi Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Trevi Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Edward Mathers	11.88%	DEF14A
Entities affiliated with New Enterprise Associates	11.74%	DEF14A
New Enterprise Associates 16, L.P.	11.74%	13D
Entities affiliated with Frazier Life Sciences	10.23%	DEF14A
BlackRock	7.97%	13F
FMR (Fidelity)	6.26%	13F
Entities affiliated with BlackRock, Inc.	5.30%	DEF14A
Entities affiliated with FMR LLC	5.06%	DEF14A
Vanguard Group	5.01%	13F
Wellington Management	4.04%	13F

Percentages above are of 128,411,048 shares outstanding, as reported by Trevi Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Trevi Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Trevi Therapeutics, Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 193 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,085 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — Trevi Therapeutics, Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Trevi Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2026.

Trevi Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.